Corcept Therapeutics
Clinical trials sponsored by Corcept Therapeutics, explained in plain language.
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. Participants are randomly assigned to receive either the drug or a placebo, and researchers measure changes in liver fat using MRI scan…
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise for Long-Term control of cushing syndrome
Disease control OngoingThis study looks at the long-term safety of relacorilant, a drug for people with Cushing syndrome. It includes 125 adults who previously completed a relacorilant study and may benefit from continued treatment. Researchers will track side effects over time to see if the drug is sa…
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC